While the biopharma IPO market has been sluggish, there may be a shift in the marketplace later this year, particularly for later-stage biopharma companies. … READ MORE >
IPO
5 things to know in life sciences: Week of April 4, 2022
From artificial intelligence opportunities to the rapidly growing market for virtual trials, each week we share five things to know in life sciences. … READ MORE >
Macroeconomic drivers for life sciences: Spring 2022 outlook
For the life sciences ecosystem to continue to thrive, leaders must reevaluate their operating environment and plan for key drivers this year. … READ MORE >
5 things to know in life sciences: Week of August 2
From gene and cell therapy developments to the latest on initial public offerings, each week we highlight five things you need to know in the life sciences industry. … READ MORE >
5 things to know in life sciences: Week of July 26
From the development of an insulin biosimilar to a new tool matching mental health providers with patients, each week we highlight five things you need to know in the life sciences industry. … READ MORE >
SPAC IPO market pauses as investors and regulators reevaluate
Now that the SPAC boom and its mid-February crest are behind us, what should we make of the current pause? How do we make sense of the slowdown? What forces will shape what happens next? … READ MORE >
CHART OF THE DAY: December is anticipated to be the biggest on record for IPOs
Special purpose acquisition companies (or SPACs) have been hot this year, but the traditional initial public offering is closing out the year even stronger. … READ MORE >
Once derided, special purpose acquisition companies go mainstream amid turbulent markets
For an increasing number of firms, the special purpose acquisition company has become a favored way to go public. SPACs are on pace for a record year of fundraising and have helped to sustain the initial public offering market even during the COVID-19 pandemic. … READ MORE >